Shinzaburo Noguchi


Ontology type: schema:Person     


Person Info

NAME

Shinzaburo

SURNAME

Noguchi

Publications in SciGraph latest 50 shown

  • 2019-04 Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC in BREAST CANCER RESEARCH AND TREATMENT
  • 2019-02 PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2018-12 ASO Author Reflections: Intraoperative Nomograms Based on One-Step Nucleic Acid Amplification in ANNALS OF SURGICAL ONCOLOGY
  • 2018-09 Intraoperative Nomograms, Based on One-Step Nucleic Acid Amplification, for Prediction of Non-sentinel Node Metastasis and Four or More Axillary Node Metastases in Breast Cancer Patients with Sentinel Node Metastasis in ANNALS OF SURGICAL ONCOLOGY
  • 2018-08 Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients in BREAST CANCER RESEARCH AND TREATMENT
  • 2018-05 Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON) in BREAST CANCER
  • 2018-04 Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC) in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2018-03 Comparison of quality of life between 2-year and 3-or-more-year administration of leuprorelin acetate every-3-months depot in combination with tamoxifen as adjuvant endocrine treatment in premenopausal patients with endocrine-responsive breast cancer: a randomized controlled trial in SUPPORTIVE CARE IN CANCER
  • 2018-01 Highly sensitive detection of ESR1 mutations in cell-free DNA from patients with metastatic breast cancer using molecular barcode sequencing in BREAST CANCER RESEARCH AND TREATMENT
  • 2017-11 A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells in BREAST CANCER RESEARCH AND TREATMENT
  • 2017-06 Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing in BREAST CANCER RESEARCH AND TREATMENT
  • 2017-02 Japanese contribution to the field of sentinel lymph node biopsy for breast cancer patients: introduction to invited articles in INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • 2016-09 Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer in BREAST CANCER
  • 2016-05 A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer in BREAST CANCER
  • 2016-05 Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2016-02 Clinical significance of breast cancer micrometastasis in the sentinel lymph node in SURGERY TODAY
  • 2016-01 Multi-gene classifiers for prediction of recurrence in breast cancer patients in BREAST CANCER
  • 2016-01 One-Step Nucleic Acid Amplification Assay for Detection of Axillary Lymph Node Metastases in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy in ANNALS OF SURGICAL ONCOLOGY
  • 2015-12 Promoter methylation of TRIM9 as a marker for detection of circulating tumor DNA in breast cancer patients in SPRINGERPLUS
  • 2015-07 C4.4A highly expressed in HER2-positive human breast cancers may indicate a good prognosis in BREAST CANCER
  • 2015-07 Mutational analysis of MED12 in fibroadenomas and phyllodes tumors of the breast by means of targeted next-generation sequencing in BREAST CANCER RESEARCH AND TREATMENT
  • 2015-04 PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients in BREAST CANCER RESEARCH AND TREATMENT
  • 2015-01 2013 clinical practice guidelines (The Japanese Breast Cancer Society): history, policy and mission in BREAST CANCER
  • 2014-11 Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2 in BREAST CANCER
  • 2014-09 Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis in ADVANCES IN THERAPY
  • 2014-05 Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer in BREAST CANCER
  • 2014-05 Lack of genomic rearrangements involving the aromatase gene CYP19A1 in breast cancer in BREAST CANCER
  • 2013-10 Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis in ADVANCES IN THERAPY
  • 2013-07 Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients in BREAST CANCER RESEARCH AND TREATMENT
  • 2013-06 A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2013-03 Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609 in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2012-12 Preoperative systemic therapy in locoregional management of early breast cancer: highlights from the Kyoto Breast Cancer Consensus Conference in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-11 Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-07 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-06 Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-04 MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-02 Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay in BREAST CANCER RESEARCH AND TREATMENT
  • 2012 Numerical Simulation and Experimental Verification for Rice Using Distinct Element Method in ASIASIM 2012
  • 2011-08 A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients in BREAST CANCER RESEARCH AND TREATMENT
  • 2011-08 Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients in BREAST CANCER RESEARCH AND TREATMENT
  • 2011-08 BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation in BREAST CANCER RESEARCH AND TREATMENT
  • 2011-07 Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts in BREAST CANCER RESEARCH AND TREATMENT
  • 2011-04 Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer in BREAST CANCER RESEARCH AND TREATMENT
  • 2011-03 Sentinel lymph node biopsy before versus after neoadjuvant chemotherapy for breast cancer in SURGERY TODAY
  • 2010-10 Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer in BREAST CANCER
  • 2010-08 Treatment strategy for metastatic breast cancer according to intrinsic subtype in INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • 2010-04 Predictive factors for anthracycline-based chemotherapy for human breast cancer in BREAST CANCER
  • 2010-01 Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group in BREAST CANCER RESEARCH AND TREATMENT
  • 2009-10 From standardization to personalization in breast cancer treatment in BREAST CANCER
  • 2009-10 Breast cancer risk assessment for possible tailored screening for Japanese women in BREAST CANCER
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.136593.b", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410800.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411582.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415479.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.416963.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.414340.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418490.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415632.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.26999.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.414944.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.260493.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412398.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415582.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.22937.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415740.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.258799.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.459801.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411898.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.272242.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410807.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.26091.3c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.260975.f", 
            "type": "Organization"
          }
        ], 
        "familyName": "Noguchi", 
        "givenName": "Shinzaburo", 
        "id": "sg:person.01030141447.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030141447.93"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T14:49", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_558.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01030141447.93'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01030141447.93'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01030141447.93'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01030141447.93'


     

    This table displays all metadata directly associated to this object as RDF triples.

    58 TRIPLES      10 PREDICATES      32 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01030141447.93 schema:affiliation Nda9405f88fe047c085927be731fd44a2
    2 https://www.grid.ac/institutes/grid.22937.3d
    3 https://www.grid.ac/institutes/grid.258799.8
    4 https://www.grid.ac/institutes/grid.260493.a
    5 https://www.grid.ac/institutes/grid.26091.3c
    6 https://www.grid.ac/institutes/grid.260975.f
    7 https://www.grid.ac/institutes/grid.26999.3d
    8 https://www.grid.ac/institutes/grid.272242.3
    9 https://www.grid.ac/institutes/grid.410800.d
    10 https://www.grid.ac/institutes/grid.410807.a
    11 https://www.grid.ac/institutes/grid.411582.b
    12 https://www.grid.ac/institutes/grid.411898.d
    13 https://www.grid.ac/institutes/grid.412398.5
    14 https://www.grid.ac/institutes/grid.414340.6
    15 https://www.grid.ac/institutes/grid.414944.8
    16 https://www.grid.ac/institutes/grid.415479.a
    17 https://www.grid.ac/institutes/grid.415582.f
    18 https://www.grid.ac/institutes/grid.415632.7
    19 https://www.grid.ac/institutes/grid.415740.3
    20 https://www.grid.ac/institutes/grid.416963.f
    21 https://www.grid.ac/institutes/grid.418490.0
    22 https://www.grid.ac/institutes/grid.459801.1
    23 schema:familyName Noguchi
    24 schema:givenName Shinzaburo
    25 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030141447.93
    26 schema:sdDatePublished 2019-03-07T14:49
    27 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    28 schema:sdPublisher Nb69b37a187524a1da9744526ac01d4e0
    29 sgo:license sg:explorer/license/
    30 sgo:sdDataset persons
    31 rdf:type schema:Person
    32 Nb69b37a187524a1da9744526ac01d4e0 schema:name Springer Nature - SN SciGraph project
    33 rdf:type schema:Organization
    34 Nda9405f88fe047c085927be731fd44a2 schema:affiliation https://www.grid.ac/institutes/grid.136593.b
    35 sgo:isCurrent true
    36 rdf:type schema:OrganizationRole
    37 https://www.grid.ac/institutes/grid.136593.b schema:Organization
    38 https://www.grid.ac/institutes/grid.22937.3d schema:Organization
    39 https://www.grid.ac/institutes/grid.258799.8 schema:Organization
    40 https://www.grid.ac/institutes/grid.260493.a schema:Organization
    41 https://www.grid.ac/institutes/grid.26091.3c schema:Organization
    42 https://www.grid.ac/institutes/grid.260975.f schema:Organization
    43 https://www.grid.ac/institutes/grid.26999.3d schema:Organization
    44 https://www.grid.ac/institutes/grid.272242.3 schema:Organization
    45 https://www.grid.ac/institutes/grid.410800.d schema:Organization
    46 https://www.grid.ac/institutes/grid.410807.a schema:Organization
    47 https://www.grid.ac/institutes/grid.411582.b schema:Organization
    48 https://www.grid.ac/institutes/grid.411898.d schema:Organization
    49 https://www.grid.ac/institutes/grid.412398.5 schema:Organization
    50 https://www.grid.ac/institutes/grid.414340.6 schema:Organization
    51 https://www.grid.ac/institutes/grid.414944.8 schema:Organization
    52 https://www.grid.ac/institutes/grid.415479.a schema:Organization
    53 https://www.grid.ac/institutes/grid.415582.f schema:Organization
    54 https://www.grid.ac/institutes/grid.415632.7 schema:Organization
    55 https://www.grid.ac/institutes/grid.415740.3 schema:Organization
    56 https://www.grid.ac/institutes/grid.416963.f schema:Organization
    57 https://www.grid.ac/institutes/grid.418490.0 schema:Organization
    58 https://www.grid.ac/institutes/grid.459801.1 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...